Tanno Luciana Kase, Calderon Moises A, Papadopoulos Nikolaos G, Sanchez-Borges Mario, Rosenwasser Lanny J, Bousquet Jean, Pawankar Ruby, Sisul Juan Carlos, Cepeda Alfonso Mario, Li James, Muraro Antonella, Fineman Stanley, Sublett James L, Katelaris Constance H, Chang Yoon-Seok, Moon Hee-Bom, Casale Thomas, Demoly Pascal
Hospital Sírio Libanês, São Paulo, Brazil; Division of Allergy, Department of Pulmonology, University Hospital of Montpellier, Montpellier, France; Pierre Louis Institute of Epidemiology and Public Health, Sorbonne Universités, Paris, France.
Section of Allergy and Clinical Immunology, Imperial College London, National Heart and Lung Institute, Royal Brompton Hospital, London, United Kingdom.
J Allergy Clin Immunol Pract. 2016 Jul-Aug;4(4):643-9. doi: 10.1016/j.jaip.2015.12.022. Epub 2016 Mar 8.
Allergy and hypersensitivity intervention management procedures, such as desensitization and/or tolerance induction and immunotherapy, have not been pondered up to now in the content of International Classification of Diseases (ICD) context because the focus has been on prioritizing the condition implementations. Tremendous efforts have been devoted to implementing allergic and hypersensitivity conditions in the forthcoming ICD-11. However, we consider that it is crucial now to have nomenclature and classification universally accepted for these procedures to be able to provide scientifically consistent proposals into the new ICD-11 platform for the best practice parameters of our specialty. With the aim of promoting a harmonized comprehension and aligning it with the ICD-11 revision, we have reviewed the definitions and concepts currently used for desensitization and/or tolerance induction and immunotherapy. We strongly believe that this review is a key instrument to support the allergy specialty identity into the ICD-11 framework and serves as a platform to perform positive quality improvement in clinical practice.
过敏和超敏反应干预管理程序，如脱敏和/或耐受性诱导及免疫疗法，目前在《国际疾病分类》（ICD）的内容中尚未得到考虑，因为重点一直放在优先实施相关病症上。在即将推出的ICD - 11中，已经为实施过敏和超敏反应病症付出了巨大努力。然而，我们认为现在至关重要的是要有被普遍接受的这些程序的命名法和分类，以便能够为我们专业的最佳实践参数向新的ICD - 11平台提供科学一致的建议。为了促进统一理解并使其与ICD - 11修订版保持一致，我们审查了目前用于脱敏和/或耐受性诱导及免疫疗法的定义和概念。我们坚信，这次审查是支持过敏专业在ICD - 11框架中的身份认同的关键工具，并作为在临床实践中进行积极质量改进的平台。
